Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03532308Phase 3Terminated
Phase 3, randomised, double-blind trial (2 arms), sponsored by Yale University. Primary endpoint: Prostate-specific Antigen. Started Nov 2018; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03532308.